With a multibillion dollar investment from Microsoft and already 4 authorship credits on PubMed, ChatGPT is poised to disrupt Medical Affairs.
2023 brings increased expectations from the FDA for patient-focused drug development (PFDD). Medical Affairs organizations need to develop new skills to put the patient voice at the center of drug, device, and diagnostic development and evaluation.
Medical Affairs professionals across the globe became first-time Innovation Olympians, responded to a bold challenge, celebrated competition, accelerated innovation together, and shared a memorable experience together.
Instead of being static representations of an event, insights can become actionable—informing what can be done to improve future events or even larger business decisions.
Influence is an inside-out game, requiring us to look inward before we lead outward.
if you start your day in work mode (4th & 5th gears), and you drive all day like that, you are going to burn out fast!
MAPS speaks with Annemarie Clegg, CMO, OPEN Health, about the evolving role of Medical Affairs in providing context for payers, regulators and policy makers whose decisions can dramatically affect which patients can access industry innovations.
How do leaders make their way to Medical Safety & Pharmacovigilance? The routes are diverse but one constant remains true: They are extremely committed to being an independent voice that amplifies their organization’s commitment to Patient Centricity.
One of the pandemic’s silver linings may well be gains in participation levels and the volume and quality of insights generated by eliminating the constraints of face-to-face interaction.
In this final article in the Leadership Perspectives series, John Pracyk interviews J&J leaders to explore a bold vision of career development that entails moving across sectors; namely, crossing over between Pharmaceuticals, Medical Devices, Vision, and Consumer Health.